reV

reV Therapeutics is a biotechnology company focused on developing novel therapies that target the circadian clock to treat a variety of serious diseases. The company's primary focus is on the REV-ERB nuclear receptors, which serve as critical regulators of the body's internal clock and metabolic processes. By modulating these receptors, reV Therapeutics aims to address unmet needs in oncology, metabolic health, and inflammatory conditions. Their approach leverages deep expertise in chronobiology to optimize drug delivery and efficacy based on biological rhythms. The company is currently advancing a pipeline of small molecule modulators through pre-clinical development.